• iPSC-Based Trial Selection for Ultrarare Disease

  2026-09-01

  Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare Leigh-like syndrome caused by poorly characterized ECHS1 variants. The platform linked cellular drug responses with subsequent clinical decision-making, illustrating how disease modeling can reduce uncertainty before enrolling patients with novel mutations in clinical trials.

• Sulfisomidine Workflows for Enzyme and Microbial Studies

  2026-09-01

  Sulfisomidine, also known as sulfamethin, connects PABA-dependent bacterial metabolism with hPON1 enzyme studies, making it a versatile reagent for mechanistic assays. This guide translates historical pharmacokinetic observations into practical workflows for reproducible inhibition, antimicrobial, cell-based, and degradation experiments.

• STING Agonist-1: From Signaling to TLS

  2026-08-31

  A translational perspective on how STING agonist-1 can help dissect the STING–TRAF2–IRF4 axis, B-cell activation, and tertiary lymphoid structure biology in cancer and inflammation research.

• CD59–JAK2–STAT3 Signaling in Pancreatic Cancer

  2026-08-31

  A 2026 study identifies CD59 as a tumor cell-intrinsic driver of pancreatic cancer rather than only a complement-protective membrane protein. The work connects CD59 to a JAK2–STAT3–CACNA1D signaling axis and shows why simultaneous targeting of CD59 or STAT3 with KRAS may help counter adaptive resistance.

• 5-Methyl-CTP Workflow for Durable mRNA

  2026-08-30

  Learn how 5-Methyl-CTP can be integrated into in vitro transcription to support more persistent, translatable mRNA for expression assays and vaccine-oriented research. The workflow also shows how to evaluate modified transcripts in engineered outer membrane vesicle delivery systems without confusing payload chemistry with carrier performance.

• Modeling Breast Cancer Relapse with PyMT ProTracer

  2026-08-29

  The reference study introduces a dual-recombinase proliferation-tracing and ablation system in spontaneous PyMT mammary tumors. By selectively removing recently proliferating cells and profiling the residual disease with single-cell RNA sequencing, the model reveals cellular and microenvironmental features associated with relapse.

• Carbapenemase Gene Transmission in CREC in Guangdong

  2026-08-28

  This study integrates gene localization, conjugation assays, mobile-element profiling, and ERIC-PCR typing to examine carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from eight teaching hospitals. Its main practical implication is that plasmid-associated blaNDM-1 and highly transferable resistance determinants may enable both rapid horizontal dissemination and persistent clonal spread across clinical settings.

• ERK Connects IFNγ Signaling to Melanoma Cell Death

  2026-08-28

  Champhekar et al. identified ERK activation as a central mediator of IFNγ-induced melanoma cell death, linking an immune cytokine signal to a stress-dependent apoptotic program. Their integrated chemical-genetic, transcriptomic, imaging, and apoptosis analyses provide a mechanistic framework for understanding tumor growth inhibition and potential determinants of immunotherapy response.

• Tofacitinib citrate: JAK-STAT Research Workflows

  2026-08-27

  Tofacitinib citrate enables controlled studies of JAK-STAT signaling, lymphocyte biology, and cytokine-driven endothelial inflammation. Its value is greatest when nanomolar immune-cell assays are separated from higher-concentration vascular stress experiments and paired with orthogonal readouts.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-08-27

  This scenario-driven guide explains how SKU K2003 supports practical apoptosis assay design, early apoptosis detection, flow cytometry apoptosis detection, and interpretation of Annexin V/PI staining. It combines assay principles, protocol parameters, controls, vendor-selection considerations, and limitations relevant to biomedical research.

• Cy3 NHS ester (non-sulfonated) Protocol Guide

  2026-08-26

  Cy3 NHS ester (non-sulfonated), SKU A8100, provides orange fluorescence for amino-group labeling of soluble proteins, peptides, and oligonucleotides when an organic co-solvent is acceptable. It is not water-soluble and should not be selected for delicate or strictly aqueous workflows unless the labeling design can tolerate DMSO or DMF.

• Chemically Modified TPO mRNA and Thrombopoiesis

  2026-08-26

  Zhang and colleagues developed chemically modified, in-vitro-transcribed thrombopoietin (TPO) mRNA and delivered it to mice in lipid nanoparticles. The treatment produced dose-dependent TPO expression, increased platelet production, and accelerated recovery from antibody-induced thrombocytopenia, supporting a transient mRNA-based strategy for stimulating thrombopoiesis.

• Niclosamide: From STAT3 Mechanism to Translation

  2026-08-25

  A translational perspective on Niclosamide as a STAT3-focused research tool, connecting Tyr-705 phosphorylation, apoptosis, cell-cycle arrest, assay strategy, model selection, and evidence-aware experimental design.

• Cerulenin Blocks Leucomycin Biosynthesis

  2026-08-25

  This 1977 study used cerulenin as a pathway-level probe to show that leucomycin production in Streptomyces kitasatoensis depends on fatty acid-like condensation chemistry. Its combination of reversible inhibition, precursor tracing, and independent protein and RNA measurements provides a useful framework for interpreting macrolide biosynthesis experiments.

• Hyperthermia–Cisplatin Therapy: Caspase-8 Mechanism

  2026-08-24

  The 2024 reference study identifies a mechanistic link between hyperthermia, cisplatin, caspase-8 accumulation, apoptosis, and pyroptosis in cancer cells. Its perturbation experiments suggest that Cullin 3-associated K63-linked polyubiquitination and p62 interactions help position caspase-8 upstream of both apoptotic and pyroptotic cell death, while downstream caspase-3 activity provides a useful functional readout.

8010 records 1/534 page Next 12345 下5页 Last page